Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives

Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence: Kristen M BeckDepartment of Dermatology, Univers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ly K, Beck KM, Smith MP, Orbai AM, Liao W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Tofacitinib psoriatic arthritis janus kinase kinase inhibitors Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/2be9896c311441df89358ff87576a385
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2be9896c311441df89358ff87576a385
record_format	dspace
spelling	oai:doaj.org-article:2be9896c311441df89358ff87576a3852021-12-02T07:14:53ZTofacitinib in the management of active psoriatic arthritis: patient selection and perspectives2230-326Xhttps://doaj.org/article/2be9896c311441df89358ff87576a3852019-08-01T00:00:00Zhttps://www.dovepress.com/tofacitinib-in-the-management-of-active-psoriatic-arthritis-patient-se-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XKaren Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence: Kristen M BeckDepartment of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA 94118, USATel +1 415 476 4701Fax +1 415 502 4126Email kristenbeckmd@gmail.comAbstract: Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib.Keywords: tofacitinib, psoriatic arthritis, janus kinase, kinase inhibitorsLy KBeck KMSmith MPOrbai AMLiao WDove Medical PressarticleTofacitinibpsoriatic arthritisjanus kinasekinase inhibitorsDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 9, Pp 97-107 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tofacitinib psoriatic arthritis janus kinase kinase inhibitors Dermatology RL1-803
spellingShingle	Tofacitinib psoriatic arthritis janus kinase kinase inhibitors Dermatology RL1-803 Ly K Beck KM Smith MP Orbai AM Liao W Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
description	Karen Ly,1 Kristen M Beck,1 Mary P Smith,1 Ana-Maria Orbai,2 Wilson Liao11Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USACorrespondence: Kristen M BeckDepartment of Dermatology, University of California San Francisco, 515 Spruce Street, San Francisco, CA 94118, USATel +1 415 476 4701Fax +1 415 502 4126Email kristenbeckmd@gmail.comAbstract: Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib.Keywords: tofacitinib, psoriatic arthritis, janus kinase, kinase inhibitors
format	article
author	Ly K Beck KM Smith MP Orbai AM Liao W
author_facet	Ly K Beck KM Smith MP Orbai AM Liao W
author_sort	Ly K
title	Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
title_short	Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
title_full	Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
title_fullStr	Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
title_full_unstemmed	Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
title_sort	tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/2be9896c311441df89358ff87576a385
work_keys_str_mv	AT lyk tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT beckkm tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT smithmp tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT orbaiam tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives AT liaow tofacitinibinthemanagementofactivepsoriaticarthritispatientselectionandperspectives
_version_	1718399509261713408

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives

Ejemplares similares